350,99 €
389,99 €
-10% with code: EXTRA
Novel Anticancer Drug Protocols
Novel Anticancer Drug Protocols
350,99
389,99 €
  • We will send in 10–14 business days.
We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular…
  • Publisher:
  • Year: 2013
  • Pages: 355
  • ISBN-10: 1489938397
  • ISBN-13: 9781489938398
  • Format: 15.2 x 22.9 x 2 cm, softcover
  • Language: English
  • SAVE -10% with code: EXTRA

Novel Anticancer Drug Protocols (e-book) (used book) | bookbook.eu

Reviews

Description

We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin(R) (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.

EXTRA 10 % discount with code: EXTRA

350,99
389,99 €
We will send in 10–14 business days.

The promotion ends in 15d.17:52:57

The discount code is valid when purchasing from 10 €. Discounts do not stack.

Log in and for this item
you will receive 3,90 Book Euros!?
  • Publisher:
  • Year: 2013
  • Pages: 355
  • ISBN-10: 1489938397
  • ISBN-13: 9781489938398
  • Format: 15.2 x 22.9 x 2 cm, softcover
  • Language: English English

We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin(R) (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.

Reviews

  • No reviews
0 customers have rated this item.
5
0%
4
0%
3
0%
2
0%
1
0%
(will not be displayed)